Pages

▼
Showing posts with label Amgen. Show all posts
Showing posts with label Amgen. Show all posts
Friday, January 10, 2014

JPM Survival Guide: DOTW Keeps the Party Going

›
The last few years have been quite a bash for biotech. Astoundingly, the NASDAQ Biotechnology Index (NBI) has added more now than it did du...
Tuesday, January 07, 2014

And The Roger Goes To ... Our Deals of the Year Winners!

›
To Claim Award: Ctrl-P, cut along border, tape to plaque (note: plaque not included). M&A of the Year: Amgen/Onyx Congratulations...
Tuesday, December 17, 2013

2013 Alliance of The Year Nominee: Amgen/Astellas

›
It's time for the IN VIVO Blog's Sixth Annual Deal of the Year! competition. This year we're once again presenting awards in th...
Thursday, December 12, 2013

2013 M&A Of The Year Nominee: Amgen/Onyx

›
It's time for the IN VIVO Blog's Sixth Annual Deal of the Year! competition. This year we're once again presenting awards in th...
Friday, October 25, 2013

DOTW Wonders: Where Have the Private Biotech Take-Outs Gone?

›
We do like a nice, frothy biotech IPO market. But is it coming at the expense of stellar acquisitions of private biotechs? We miss the kin...
Friday, August 30, 2013

DOTW Looks At How 2013 Biotech Deal Stats Stack Up After Amgen/Onyx

›
Quick! What's large and vanilla and a late summer treat? It’s the last week of summer, and while one might expect business develop...
Friday, July 26, 2013

Deals Of the Week, Once Again, Ponders Biosimilars

›
Teva Pharmaceutical Industries Ltd.’s and Lonza Group’s announcement on July 25 that they were formally ending their four-year-old...